You are here

Shire

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

Endpoints

hereditary angiodema

Flag link:

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

Endpoints

Flag link:

Kamada slumps after Shire hands back rights

Kamada slumps after Shire hands back rights

BioPharma Dive

alpha-1 antitrypsin

graft vs host disease

Flag link:

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Seeking Alpha

Flag link:

Shire writes off a shot at long-acting hemophilia drug after small study flops

Shire writes off a shot at long-acting hemophilia drug after small study flops

Endpoints

Xenetic Biosciences

clinical trials

Flag link:

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Endpoints

Flag link:

Shire commits up to $535M for Parion's dry eye drug

Shire commits up to $535M for Parion's dry eye drug

BioPharma Dive

dry eye disease

Flag link:

Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch

Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch

Fierce Pharma

hereditary angiodema

Flag link:

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Fierce Pharma

dry eye disease

Flag link:

About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet

About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet

Fierce Pharma

Ariad Pharmaceuticals

Flag link:

Shire Rises on Encouraging Angioedema Results

Shire Rises on Encouraging Angioedema Results

TheStreet.com

Flag link:

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

Endpoints

Flag link:

Baxalta pushes Shire to record revenues

Baxalta pushes Shire to record revenues

BioPharma Dive

Flag link:

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

Endpoints

Flag link:

Shire to pay $350 million for kickback allegations

Shire to pay $350 million for kickback allegations

Marketwatch

False Claims Act

Flag link:

Shire deals RNA platform to Cambridge's RaNa for equity stake

Shire deals RNA platform to Cambridge's RaNa for equity stake

Bizjournals.com

drug development

Flag link:

Allergan Is Losing Its No. 2 Product More Rapidly Than Expected

Allergan Is Losing Its No. 2 Product More Rapidly Than Expected

Seeking Alpha

dry eye disease

Flag link:

The Most Expensive Drugs of 2016

The Most Expensive Drugs of 2016

Motley Fool

Gilead Sciences

Bristol-Myers Squibb

Flag link:

Shire's Vonvendi controls surgical bleeding

Shire's Vonvendi controls surgical bleeding

BioPharma Dive

surgical bleeding

Flag link:

Allergan's Restasis Faces Dry Eye Threat: Examining XIIDRA's Initial Sales Trends

Allergan's Restasis Faces Dry Eye Threat: Examining XIIDRA's Initial Sales Trends

Seeking Alpha

dry eye disease

Flag link: